ArticleThe Journal of allergy and clinical immunology2017

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.

Jennifer A Regan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.